BNP Paribas Financial Markets Acquires Shares of 203,595 Nkarta, Inc. (NASDAQ:NKTX)

BNP Paribas Financial Markets bought a new position in shares of Nkarta, Inc. (NASDAQ:NKTX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 203,595 shares of the company's stock, valued at approximately $507,000. BNP Paribas Financial Markets owned about 0.29% of Nkarta as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Alyeska Investment Group L.P. grew its holdings in Nkarta by 23.0% during the 4th quarter. Alyeska Investment Group L.P. now owns 1,334,696 shares of the company's stock worth $3,323,000 after acquiring an additional 250,000 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Nkarta by 41.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 23,958 shares of the company's stock worth $60,000 after purchasing an additional 7,030 shares in the last quarter. Hsbc Holdings PLC lifted its position in shares of Nkarta by 102.8% during the fourth quarter. Hsbc Holdings PLC now owns 73,845 shares of the company's stock worth $171,000 after purchasing an additional 37,433 shares in the last quarter. Stifel Financial Corp grew its stake in shares of Nkarta by 11.5% during the fourth quarter. Stifel Financial Corp now owns 90,811 shares of the company's stock valued at $226,000 after purchasing an additional 9,359 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Nkarta by 101.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 569,357 shares of the company's stock valued at $1,417,000 after purchasing an additional 286,181 shares in the last quarter. 80.54% of the stock is currently owned by institutional investors and hedge funds.

Nkarta Trading Up 0.3%

NASDAQ:NKTX traded up $0.01 during mid-day trading on Thursday, hitting $1.77. 47,813 shares of the company's stock were exchanged, compared to its average volume of 1,059,173. The firm has a market capitalization of $125.31 million, a P/E ratio of -0.94 and a beta of 0.81. Nkarta, Inc. has a fifty-two week low of $1.31 and a fifty-two week high of $8.23. The company has a 50 day simple moving average of $1.81 and a 200-day simple moving average of $2.12.

Nkarta (NASDAQ:NKTX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.01. As a group, analysts expect that Nkarta, Inc. will post -1.7 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have commented on NKTX shares. HC Wainwright reaffirmed a "buy" rating and set a $18.00 target price on shares of Nkarta in a report on Thursday, March 27th. Stifel Nicolaus decreased their price target on shares of Nkarta from $15.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, March 27th. William Blair reissued a "market perform" rating on shares of Nkarta in a report on Thursday, May 15th. Finally, Needham & Company LLC cut their price target on Nkarta from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Thursday, May 15th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $14.67.

Nkarta Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.